ERDHEIM-CHESTER DISEASE
Clinical trials for ERDHEIM-CHESTER DISEASE explained in plain language.
Never miss a new study
Get alerted when new ERDHEIM-CHESTER DISEASE trials appear
Sign up with your email to follow new studies for ERDHEIM-CHESTER DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets rare immune diseases that resist standard care
Disease control Recruiting nowThis study tests a drug called cobimetinib in children and adults with histiocytic disorders that have come back or not responded to other treatments. Cobimetinib blocks a faulty growth signal inside cells. The goal is to see if the drug can shrink tumors and slow the disease. Ab…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: PHASE2 • Sponsor: Carl Allen • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Could a melanoma drug combo work for other rare cancers?
Disease control Recruiting nowThis study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific BRAF V600 gene change. About 30 people will take the drugs to see if their tumors shrink or stop growing. The goal is to find new uses fo…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated May 11, 2026 20:48 UTC
-
Researchers launch registry to unlock mysteries of rare histiocyte diseases
Knowledge-focused Recruiting nowThis study creates a registry for up to 500 people with Erdheim-Chester disease and other histiocytoses. Researchers will collect medical information and patient experiences over time to better understand these rare conditions and how treatments affect health and quality of life.…
Matched conditions: ERDHEIM-CHESTER DISEASE
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 17, 2026 02:06 UTC
-
New PET tracer could reveal hidden cancer spots
Knowledge-focused Recruiting nowThis early-phase study is testing a new imaging agent called [68Ga]-pentixafor to see how well it lights up certain blood cancers and solid tumors on PET/CT scans. About 30 people with conditions like multiple myeloma, non-Hodgkin lymphoma, or histiocytic neoplasms will receive t…
Matched conditions: ERDHEIM-CHESTER DISEASE
Phase: EARLY_PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 13, 2026 15:59 UTC